Millennium | Clinicians | Oncology | VELCADE

	Overview
	VELCADE^®
	Research and Development
	Clinical Trials
	Resources for Patients

Indication: VELCADE^® (bortezomib) for Injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

For further information about VELCADE and Mantle Cell Lymphoma (MCL), select a menu item in the table below.

Menu Item	Topic
Mechanism	VELCADE: mechanism of action
Disease Background	Background on MCL
PINNACLE Trial Design and Results	PINNACLE phase 2 trial overview
Safety Profile	MCL specific and integrated analysis of safety
Dosing Schedule	Dosing for MCL
Dose Modification Guidlines	Dosing recommendations for managing side effects
Handling and Administration	Handling and administration guidelines
Important Safety Information	Contraindications, warnings, and precautions
Reimbursement	Reimbursement assistance program
Additional Information	Downloadable files and phone number for VELCADE and MCL information
References	Journal articles and other cited sources

For full Prescribing Information click here. (pdf) (74KB)

For further information about VELCADE^® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).